Literature DB >> 7228454

Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection.

J Kanto, H Allonen, K Koski, M Koulu, R Lammintausta, R Mäntylä, T Kleimola, T Siirtola.   

Abstract

The pharmacokinetics of dihydroergotamine (DHE) was studied in healthy volunteers (n = 6) and in neurological patients (n = 12). After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min). In saliva (dose 1.0 mg, n =6) and cerebrospinal fluid (dose 0.5 mg, n =12) there were no measurable amounts of DHE after a single i.v. dose. The 32-h cumulative urinary excretion was 0.02-0.04% of the 1.0 mg intravenous dose. In one subject renal (0.18 ml/min) and extrarenal (692.9 ml/min) clearance of DHE was calculated. According to our results DHe is probably eliminated mainly by hepatic metabolism. The pharmacokinetic properties of DHE indicate a fast clinical response without a cumulative action.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7228454

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

1.  Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.

Authors:  M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

2.  Pharmacological actions of the main metabolites of dihydroergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.

Authors:  H de Marées; D Welzel; A de Marées; U Klotz; K U Tiedjen; G Knaup
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.